The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies

Background: Among the several therapeutic options assessed for the treatment of coronavirus disease 2019 (COVID-19), tocilizumab (TCZ), an antagonist of the interleukine-6 receptor, has emerged as a promising therapeutic choice, especially for the severe form of the disease. Proper synthesis of the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alberto Enrico Maraolo, Anna Crispo, Michela Piezzo, Piergiacomo Di Gennaro, Maria Grazia Vitale, Domenico Mallardo, Luigi Ametrano, Egidio Celentano, Arturo Cuomo, Paolo A. Ascierto, Marco Cascella
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
R
Acceso en línea:https://doaj.org/article/40df4318293449579a3b4392e929bcbd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares